MASLD is prevalent in T2DM patients, with a 65% occurrence rate, and poses a higher risk for severe liver diseases. The study analyzed 3,836 T2DM patients, identifying key predictors like BMI, ...
SAN DIEGO — An artificial intelligence (AI)–driven algorithm may be able to accurately detect early-stage metabolic dysfunction–associated steatotic liver disease (MASLD) based on imaging findings and ...
"These novel findings suggest that targeted interventions for improving HDL, blood pressure, obesity, and dyslipidemia could mitigate MASLD risk." — Wu et al., Nutrition, 2024 Investigators conducted ...
The causal biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD) and their clinical value remain unclear. In this study, we aimed to identify biomarkers for MASLD and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback